VOR
NASDAQVor Biopharma Inc.
Price$24.00+0.32 (+1.33%)
01:30 PM07:45 PM
News · 26 weeks60-17%
2026-03-012026-08-23
Mix2690d
- Insider11(42%)
- Other10(38%)
- SEC Filings4(15%)
- Leadership1(4%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Vor Biopharma Inc.SCHEDULE 13G/A - Vor Biopharma Inc. (0001817229) (Subject)
- SECSEC Form 10-Q filed by Vor Biopharma Inc.10-Q - Vor Biopharma Inc. (0001817229) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Vor Biopharma Inc.SCHEDULE 13G/A - Vor Biopharma Inc. (0001817229) (Subject)
- SECSEC Form SCHEDULE 13G filed by Vor Biopharma Inc.SCHEDULE 13G - Vor Biopharma Inc. (0001817229) (Subject)
- PRVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on August 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 32,550 shares of Vor Bio’s common stock and restricted stock units ("RSUs") representing the right to receive an aggregate of 6,900 shares of Vor Bio’s common stock to 5 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Induc
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Vor Biopharma Inc.SCHEDULE 13D/A - Vor Biopharma Inc. (0001817229) (Subject)
- INSIDERLarge owner Ra Capital Management, L.P. exercised 2,100,000 in-the-money shares at a strike of $0.00 and sold $4,207 worth of shares (213 units at $19.75) (SEC Form 4)4 - Vor Biopharma Inc. (0001817229) (Issuer)
- INSIDERSEC Form 4 filed by Director Zaccardelli David4 - Vor Biopharma Inc. (0001817229) (Issuer)
- INSIDERSEC Form 3 filed by new insider Zaccardelli David3 - Vor Biopharma Inc. (0001817229) (Issuer)
- SECVor Biopharma Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Vor Biopharma Inc. (0001817229) (Filer)
- PRVor Bio Appoints David Zaccardelli to Board of DirectorsBOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of David Zaccardelli, Pharm.D., to its Board of Directors. With more than 20 years of biopharmaceutical leadership experience, Dr. Zaccardelli has successfully built and led companies through late-stage development, regulatory approval, and commercial launch. "We are excited to welcome David to the Board of Directors at an important stage in the company’s evolution," said Jean-Paul Kress, M.D., Chairman and Chief Executive Officer of Vor Bio. "David is a proven biotech operator with a distinguished track r
- PRVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on July 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 71,200 shares of Vor Bio’s common stock and restricted stock units ("RSUs") representing the right to receive an aggregate of 15,150 shares of Vor Bio’s common stock to 7 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Induce
- INSIDERSEC Form 4 filed by Director Ra Capital Management, L.P.4 - Vor Biopharma Inc. (0001817229) (Issuer)
- INSIDERSEC Form 4 filed by Director Detheux Michel4 - Vor Biopharma Inc. (0001817229) (Issuer)
- INSIDERSEC Form 4 filed by Director Namouni Fouad4 - Vor Biopharma Inc. (0001817229) (Issuer)
- INSIDERSEC Form 4 filed by Director Joustra Wouter4 - Vor Biopharma Inc. (0001817229) (Issuer)
- INSIDERSEC Form 4 filed by Director Kalir Erez4 - Vor Biopharma Inc. (0001817229) (Issuer)
- INSIDERSEC Form 4 filed by Director Cumbo Alexander4 - Vor Biopharma Inc. (0001817229) (Issuer)
- INSIDERSEC Form 4 filed by Director Beckman Daniella4 - Vor Biopharma Inc. (0001817229) (Issuer)
- INSIDERSEC Form 4 filed by Director Levin Andrew David4 - Vor Biopharma Inc. (0001817229) (Issuer)
- SECVor Biopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Vor Biopharma Inc. (0001817229) (Filer)
- SECVor Biopharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Vor Biopharma Inc. (0001817229) (Filer)
- PRTelitacicept Receives NMPA Approval for the Treatment of Sjögren's Disease in ChinaFirst regulatory approval for Sjögren's disease (SjD) First and only approved therapy for SjD in China Approval based on positive Phase 3 results generated by collaborator RemeGen demonstrating statistically significant and clinically meaningful improvements in both ESSDAI and ESSPRI SjD marks the fifth indication approval for telitacicept BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, and RemeGen Co., Ltd., (HKEX: 9995, SHA: 688331) today announced that China's National Medicinal Products Administration (NMPA) has approved telitacicept for the treatment of adult patients with Sj
- PRTelitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in ChinaFirst and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN) Approval based on positive interim Phase 3 TELIGAN results generated by collaborator RemeGen and recently published in The New England Journal of Medicine IgAN marks the fourth indication approval for telitacicept BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, and RemeGen Co., Ltd., (HKEX: 9995, SHA: 688331) today announced that China's National Medicinal Products Administration (NMPA) has conditionally approved telitacicept for the treatment of adult patients with IgAN. The conditional approval is s
- PRVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)BOSTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on June 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 61,050 shares of Vor Bio's common stock and restricted stock units ("RSUs") representing the right to receive an aggregate of 12,900 shares of Vor Bio's common stock to 10 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 202
VOR FAQ
7 questionsWhat does Vor Biopharma Inc. do?
Vor Biopharma, Inc., early-stage cell therapy company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Where does VOR stock trade?
Vor Biopharma Inc. (VOR) is listed on NASDAQ.What sector and industry is VOR in?
Vor Biopharma Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Vor Biopharma Inc. go public?
Vor Biopharma Inc. (VOR) completed its IPO in 2021.What are analysts saying about VOR?
Vor Biopharma Inc. has had 8 recent analyst actions on file. The most recent action was from Jefferies: Buy on 2026-03-30. Recent price targets range from $900.00 to $4300.00.What companies are similar to VOR?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare VOR side-by-side with any of them on Quantisnow.How can I track VOR on Quantisnow?
Quantisnow aggregates Vor Biopharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VOR to receive live email and push alerts on every new disclosure.